Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis Phase III trial for next-gener…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis Phase III trial for next-gener…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Wed, 11/12/2025 – 23:04
Read more about Novartis Phase III trial for next-gener…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Wed, 11/12/2025 – 23:04
Read more about Novartis Phase III trial for next-gener…
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis
Mon, 11/10/2025 – 15:33
Read more about Novartis opens new radioligand therapy manufacturing facility in California as par…
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis
Mon, 11/10/2025 – 15:33
Read more about Novartis opens new radioligand therapy manufacturing facility in California as par…
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Tue, 11/04/2025 – 07:19
Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Tue, 11/04/2025 – 07:19
Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Tue, 11/04/2025 – 07:19
Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
Wed, 10/29/2025 – 15:34
Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in…
